AIRS vs APYX
AIRS: AirSculpt operates a proprietary, minimally invasive body contouring platform that removes fat and tightens skin through 31 treatment centers, competing with traditional liposuction and non-surgical fat reduction while benefiting from rising GLP-1 drug adoption. APYX: Apyx Medical provides advanced helium plasma-based surgical technology for cosmetic body contouring and hospital-based electrosurgical procedures.
Side-by-side fundamentals
| Metric | AIRS | APYX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.82 | $3.91 | |
| Market cap as of 2026-07-23 | $340M | $163M | |
| Net margin as of 2026-07-23 | -7.4% | -16.4% | AIRS higher |
| Gross margin as of 2026-07-23 | +66.1% | +63.1% | AIRS higher |
| Operating margin as of 2026-07-23 | -7.8% | -7.7% | APYX higher |
| ROE as of 2026-07-23 | -12.4% | -90.6% | AIRS higher |
| ROA as of 2026-07-23 | -5.9% | -14.9% | AIRS higher |
| Debt / equity as of 2026-07-23 | 0.45 | 2.74 | AIRS lower |
| Revenue growth (YoY) as of 2026-07-23 | -11.8% | +18.2% | APYX higher |
| Revenue CAGR (3y) SEC XBRL | -3.5% | +5.9% | APYX higher |
| Dividend yield as of 2026-07-23 | +0.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | n/a | |
| Beta as of 2026-07-23 | 2.40 | 1.40 | |
| 1-year return as of 2026-07-22 close | -13.4% | +73.8% | APYX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.